WO2001000189A3 - Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments - Google Patents

Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments Download PDF

Info

Publication number
WO2001000189A3
WO2001000189A3 PCT/EP2000/005575 EP0005575W WO0100189A3 WO 2001000189 A3 WO2001000189 A3 WO 2001000189A3 EP 0005575 W EP0005575 W EP 0005575W WO 0100189 A3 WO0100189 A3 WO 0100189A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
metabolism
influence
active agents
medicaments
Prior art date
Application number
PCT/EP2000/005575
Other languages
German (de)
French (fr)
Other versions
WO2001000189A2 (en
Inventor
Rudi Gruetzmann
Ulrich Mueller
Original Assignee
Bayer Ag
Rudi Gruetzmann
Ulrich Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Rudi Gruetzmann, Ulrich Mueller filed Critical Bayer Ag
Priority to AU56829/00A priority Critical patent/AU5682900A/en
Publication of WO2001000189A2 publication Critical patent/WO2001000189A2/en
Publication of WO2001000189A3 publication Critical patent/WO2001000189A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of a combination of at least one selected MTP inhibitor (component A) and active agents that influence the metabolism (component B) for treating diseases, to medicaments containing this combination and to the production thereof.
PCT/EP2000/005575 1999-06-25 2000-06-16 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments WO2001000189A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56829/00A AU5682900A (en) 1999-06-25 2000-06-16 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929012A DE19929012A1 (en) 1999-06-25 1999-06-25 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and metabolically active drug
DE19929012.1 1999-06-25

Publications (2)

Publication Number Publication Date
WO2001000189A2 WO2001000189A2 (en) 2001-01-04
WO2001000189A3 true WO2001000189A3 (en) 2001-08-02

Family

ID=7912418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005575 WO2001000189A2 (en) 1999-06-25 2000-06-16 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments

Country Status (3)

Country Link
AU (1) AU5682900A (en)
DE (1) DE19929012A1 (en)
WO (1) WO2001000189A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG165154A1 (en) * 2002-02-28 2010-10-28 Japan Tobacco Inc Ester compound and medical use thereof
MXPA04011930A (en) * 2002-05-31 2005-03-31 Yamanouchi Pharma Co Ltd Tetrahydropyran derivative.
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc Ester derivative and medicinal use thereof
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
WO2001000189A2 (en) 2001-01-04
DE19929012A1 (en) 2000-12-28
AU5682900A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
EP1378240A3 (en) Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma
BG106075A (en) Use of cyp2d6 inhibitors in combination therapies
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO1999005096A3 (en) Urokinase inhibitors
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
EP2261200A3 (en) Modified forms of pharmacacologically active agents and uses therefor
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
EP1449834A3 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
SI1509232T1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
ATE397445T1 (en) SYNERGISTIC COMBINATIONS CONTAINING A RENIN INHIBITOR FOR CARDIOVASCULAR DISEASES
HK1059213A1 (en) Treatment of type 2 diabetes with inhibitors of dipetidyl peptidase iv
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
MXPA02006826A (en) Cell division inhibitors and process for producing the same.
EP1419785A4 (en) Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
YU63699A (en) Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent
WO2002034201A3 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
EP1099442A3 (en) Methods of administering apo B-secretion/MTP inhibitors
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
WO2002040016A8 (en) Association of calpain inhibitors and reactive oxygen species trapping agents
MXPA03001455A (en) Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity.
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
GB9907571D0 (en) Compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP